The Impact of DDI on the Cancer Patient
Cancer patients are often prescribed more than one drug and the need to elucidate potential harmful interactions...
Anticoagulation Drugs
Management of VTE beyond 12 months in patients with cancer-associated thrombosis
During the ICTHIC webinar, “Long-term treatment & DDI implications in the management of CAT,” Dr. Luis...
The impact of warfarin on overall survival in cancer patients with VTE
During the 11th ICTHIC, 2022, Jeffrey Zwicker talked about the impact of warfarin on overall survival (OS) in cancer...
Low-dose apixaban as secondary prophylaxis in patients with cancer: is it safe?
Recurrent venous thromboembolism (VTE) and major bleeding are the two major challenges in managing cancer-associated...
Does warfarin increase overall survival compared to LMWH in CAT treatment?
The treatment of cancer-associated thrombosis (CAT) has changed over the last 20 years, going from warfarin up to the...
Use of direct oral anticoagulants in patients with atrial fibrillation and concomitant active cancer
Atrial fibrillation (AF) is common in patients with cancer, and up to one in every four persons with AF has comorbid...
Does the use of direct oral anticoagulants improve adherence compared to low-molecular-weight heparin (LMWH) in patients with cancer?
Patients with cancer represent a major challenge for venous thromboembolism (VTE) treatment because of their higher...
Use of tinzaparin in CAT patients with metastatic disease: a post hoc analysis of the CATCH trial
Introduction The management of cancer-associated thrombosis (CAT) is tricky because of the high risk of recurrent...
Venous thromboembolism: News from the Annual Meeting of the American Society of Hematology (ASH) on prevention and treatment
The Annual Meeting of the American Society of Hematology (ASH) was held on 7−10 December 2019 in Orlando (FL, USA)....